Vivet Therapeutics, a Paris, France-based clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders, received EUR 4.9M in funding.
The French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance provided the financing.
The company intends to use the funds to further develop its gene therapy product VTX-806 as an effective treatment option to stop or reverse disease progression over the long-term, or potentially cure CTX in patients.
Founded in 2016 by CEO Dr Jean-Philippe Combal and CSO Dr Gloria Gonzalez-Aseguinolaza, Vivet Therapeutics is a clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic conditions, including Wilson’s Disease. Its gene therapy platform uses recombinant adeno-associated viruses (rAAVs) as vectors and has initiated two clinical programs and four pre-clinical assets to date. Its most advanced therapy is VTX-801, a novel gene therapy for Wilson’s Disease, with key clinical read-outs expected by the end of 2024.
Vivet Therapeutics is backed by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer Inc., Columbus Venture Partners, Ysios Capital, Kurma Partners and Eurazeo.
Commenting on the news, Gloria Gonzalez said: “Our commitment to developing treatment options for metabolic disorders is demonstrated by our lead clinical program, VTX-801 which targets Wilson Disease, alongside a second program, VTX-806, which is in development as a potential treatment option for CTX patients. Our advanced pipeline highlights our ability to provide strong translational support for rare genetic disorders and patients’ needs, notably with the help of the CTX Alliance and the Spanish CTX patient association.”
FinSMEs
01/02/2024